ArticleEuropean journal of haematology2026
SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe aimed to investigate drug response of sodium-glucose transport protein-2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM.
methodsWe conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the comparative risk of MM between SGLT2i exposure and dipeptidyl peptidase-4 inhibitors (DPP4i) exposure. Additionally, we conducted differential gene expression analysis with drug responses in cell lines.
resultsWe observed SGLT2i compared with DDP4i exposure was associated with a reduced risk of MM in the general population (hazard ratios [HRs] ≤ 0.37, p < 0.001); and subpopulations defined by age, gender, race, deficiency anemia, renal failure, obesity, normal weight, and patients with monoclonal gammopathy of undetermined significance (HRs ≤ 0.49, p ≤ 0.032). Moreover, we revealed 450 and 660 unique differentially expressed genes (DEGs) associated with SGLT2i and DPP4i, respectively. We identified that MM-associated DEGs were significantly enriched in unique DEGs of SGLT2i compared with DPP4i (odds ratio = 2.0, p = 0.03). We found consistent DEGs between SGLT2i vs. control and normal vs. MM patients (e.g., AKT1, PHLPP2, CFD, FBLN2 proteasome genes, etc.) that regulate cell cycle, ubiquitination-proteasome system (UPS), and cell adhesion activities. SGLT2i showed potential beneficial effects in preventing MM, which could be due to SGLT2-mediated tumor-suppressing activities for MM from various aspects.
conclusionSGLT2i is associated with a lower risk of MM in patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.